AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02688907
Drug: AZD1775
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage and Schedule : AZD1775 175 mg BID per os every 12 hours (x 6 doses, 3 days) administered days 1-3 the first \& second weeks every 21 days Patients will continue to receive study treatment as described above, until they demonstrate objective disease progression (determined by RECIST 1.1) or they meet any other discontinuation criteria.
Trial: NCT02640157
Drug: ABT-493/ABT-530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; ABT-493 coformulated with ABT-530
Trial: NCT01931150
Drug: oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03451760
Drug: Feru-guard 100M
RxNorm normalized name: Clinda-Guard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feru-guard is a dietary supplement commercially available in Japan in the form of a 1.5 g instant powder packet that is sold in health clinics and directly by Glovia Co. Ltd to patients on doctor's recommendation. The current study will use Feru-guard in the form of a 280 mg hard gel capsule that contains the same amount of the active ingredients (ferulic acid and Angelica archangelica) as the 1.5 g packets. In order to conduct a double-blind, placebo-controlled trial, Feru-guard is contained in opaque, hard gel capsules which allows for better matching of characteristics and improved blinding than studies using powder. Feru-guard will be supplied by Glovia, Co. Ltd., in Tokyo, Japan.
Trial: NCT01213160
Drug: AZD4547
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film coated tablet, PO, twice daily
Trial: NCT00723021
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x placebo tablets + placebo oral dispersion, single dose.
Trial: NCT01502020
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: Topical Cream Dosage: Placebo Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
Trial: NCT04349761
Drug: MyMD1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isomyosamine 5mg capsules
Trial: NCT04349761
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00352911
Drug: Placebo for VGX-410 (Mifepristone)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00087178
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm 1: cyclophosphamide 600 mg/m2 IV every 21 days for 4 cycles; Arm 2: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Trial: NCT00087178
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fluorouracil 500 mg/m2 IV every 21 days for 6 cycles
Trial: NCT04079790
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing unit dose of placebo matching of gepotidacin will be administered orally with 240 mL of water.
Trial: NCT02715908
Drug: LBEC0101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50mg
Trial: NCT02053311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04374565
Drug: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pathogen reduced SARS-CoV-2 convalescent plasma (1-2 units; \~200 mL each for a total of 200-400mls) given preferably in one day, but allowable to be given over 2 days if clinical circumstances delay infusions in 1 day), with titer to be determined after the unit has been infused.
Trial: NCT02647047
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 1000 mg of acetaminophen 40 minutes before ending of surgery followed by intravenous administration of 1000 mg every 8 hours
Trial: NCT02647047
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of a non-steroidal antinflammatory drug (ketorolac 30 mg) as a rescue therapy
Trial: NCT02647047
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural continuous epidural infusion of sufentanil 50 mcg/mL 1 mL
Trial: NCT00381277
Drug: Gatorade
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01389427
Drug: Torisel dose 15 mg and R-CHOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Trial: NCT01389427
Drug: Torisel dose 15 mg and R-FC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Trial: NCT01389427
Drug: Torisel dose 15 mg and R-DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Trial: NCT01389427
Drug: Torisel dose 50 mg and R-CHOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Trial: NCT01389427
Drug: Torisel dose 75 mg and R-CHOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Trial: NCT01389427
Drug: Torisel dose 50 mg and R-FC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Trial: NCT01389427
Drug: Torisel dose 75 mg and R-FC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Trial: NCT01389427
Drug: Torisel dose 50 mg and R-DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Trial: NCT01389427
Drug: Torisel 75 mg and R-DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Trial: NCT00109382
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02910739
Drug: MK-8931
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8931 40 mg
Trial: NCT00826839
Drug: Oral contraceptive pill and microdose lupron
RxNorm normalized name: Desogen (contraceptive) Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desogestrel/ethinyl estradiol tablets, 0.15 mg/0.03 mg, one tablet by mouth daily for 14 days Leuprolide acetate 40 µg by subcutaneous injection twice a day during ovarian stimulation (approximately 14 days)
Trial: NCT02482077
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir 90 mg /Sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily
Trial: NCT00826839
Drug: E2 patch/antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol transdermal system 0.1 mg/day (25 cm2 patch. Patch changed every other day x 3. Final patch left on for about 7 days. Total duration of therapy approximately 14 days.~Gonadotropin-releasing hormone antagonist 0.25 mg subcutaneously every other day for 3 total doses.
Trial: NCT02179645
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02179645
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00220103
Drug: epirubicin, capecitabine, cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04182919
Drug: Phlai
RxNorm normalized name: Mycobacterium phlei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each capsule contains 4 mg compound D. Using orally in the evening everyday in 4 weeks
Trial: NCT03635593
Drug: CBD+THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to CBD+THC 10mg (CBD 5mg + THC) for 12 weeks. Participants will start with 1, 10mg CBD+THC (5mg+5mg) capsule per day and self- titrate up to 8, 10mg CBD+THC (5mg+5mg) capsules to a maximum of 80mg (40mg CBD + 40mg THC) per day as needed.
Trial: NCT04182919
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Like Phlai capsule extract : :PVP K30, Calcium carbonate, Dibasic calcium phosphate, Sodium starch glycolate, Colloidal silicon dioxide, Ethanol 96%, Purified water, Magnesium stearate. Not having compound D. Using orally in the evening everyday in 4 weeks
Trial: NCT01482559
Drug: Dopamine hydrochloride
RxNorm normalized name: Dopamine Hydrochloride
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active drug substance 1.5 mg in 1 mL IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
Trial: NCT01482559
Drug: Dextrose 5%
RxNorm normalized name: Dextrose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
Trial: NCT04643886
Drug: GEM103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological
Trial: NCT02585440
Drug: CMX157
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT02585440
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT01072591
Drug: MEDI-578
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion, once
Trial: NCT01072591
Drug: Placebo for MEDI-578
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion, once
Trial: NCT02953548
Drug: GWP42003-P
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Trial: NCT01023178
Drug: 17beta Estradiol
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pill given daily at increasing doses every 6 months for 18 months.
Trial: NCT01023178
Drug: 17Beta Estradiol - transdermal
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen patch, started at low dose with increasing doses eery 6 months for 18 months
Trial: NCT00125281
Drug: S-adenosyl-methionine (SAMe) capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04585776
Drug: LY900014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00911287
Drug: Oxymorphone extended release
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Medication: Oxymorphone ER 5 mg, 10 mg, and 20 mg tablets. Rescue Medication: Oxymorphone IR 5 mg tablets. Treatment will consist of up to 6 months of dosing with oxymorphone ER.
Trial: NCT01108107
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle
Trial: NCT05017844
Drug: KSR-001-04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop to both eyes four times a day for 12 weeks
Trial: NCT00518375
Drug: Rapamune® (Sirolimus)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00518375
Drug: Neoral® (Cyclosporine)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00518375
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left up to local practice but steroids are typically used perioperatively
Trial: NCT00791531
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral methotrexate 5mg once daily for 5 consecutive days
Trial: NCT05017844
Drug: KSR-001-02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop to both eyes four times a day for 12 weeks
Trial: NCT05017844
Drug: KSR-001-03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop to both eyes four times a day for 12 weeks
Trial: NCT00680784
Drug: HKT-500 Ketoprofen Topical Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HKT-500 Ketoprofen Topical Patch
Trial: NCT00824447
Drug: Oralgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: allergen solution sublingually
Trial: NCT03955549
Drug: Treatment As Usual (TAU)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment As Usual (TAU) consists of psychiatric management by a clinical team including at least one psychiatrist and one psychologist. Treatment involves antipsychotic medication, regular office-based contacts with the clinical team for treatment monitoring, recreational group activities, and unstructured psycho-educational groups. Participants in the interventional groups also will receive TAU.~Medications: In order to standardize treatment, Risperidone (Risperdal ) will be used as the antipsychotic medication in all three groups with a dose up to 6-8 milligrams according to clinical severity. The same dose will be used for 1 month prior to starting interventions). In case of occurrence of mild extrapyramidal symptoms associated with high doses of risperidone, an anticholinergic drug (Benztropine) might be used.
Trial: NCT03055936
Drug: Levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa 50 mg or 100 mg or 150 mg
Trial: NCT03055845
Drug: STA363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STA363, containing 3 different doses of active ingredient, in a volume of 1.5 mL. Administered as intradiscal injection.
Trial: NCT03055845
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo solution with identical appearance to the test product, used as reference treatment. Administered as intradiscal injection.
Trial: NCT00688103
Drug: ETN+MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etanercept (25 mg, twice/week, s.c.) combined with methotrexate (6-8 mg/week)
Trial: NCT02904031
Drug: l-leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01924234
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01047423
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg encapsulated once daily for 12 weeks
Trial: NCT01047423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated oral once daily for 12 weeks
Trial: NCT01871285
Drug: Placebo film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo buccal film
Trial: NCT01871285
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo capsules matching the over-encapsulated morphine sulfate and oxycodone tablets
Trial: NCT03444584
Drug: MEDI0382
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous dose of MEDI0382 (titrated up from 100 μg for 7 days to 200 μg for 7 days and to 300 μg for 14 days).
Trial: NCT03444584
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous dose of placebo matched to MEDI0382.
Trial: NCT03444584
Drug: Dapaglifozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of dapaglifozin 10 mg tablet.
Trial: NCT02711072
Drug: control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 100 µ of intrathecal Morphine+ infiltration catheter with saline 5 ml/h
Trial: NCT02711072
Drug: infiltration group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 1ml of saline + infiltration catheter with 5 ml/h of Bupivacaïne 0,125%.
Trial: NCT01461616
Drug: NPH
RxNorm normalized name: ZENPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: equal doses of NPH insulin, insulin Detemir and insulin glargine injection
Trial: NCT02542969
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02542969
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02542969
Drug: MGL-3196
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03675724
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01005771
Drug: GF-001001-00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GF-001001-00 2%, 1% and 0.25% twice daily for 7 days
Trial: NCT01005771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT03878082
Drug: IVPCA
RxNorm normalized name: Intravenous Patient-Controlled Analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pain control with IVPCA
Trial: NCT00691405
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation solution BID
Trial: NCT00691405
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhalation solution QD
Trial: NCT00238524
Drug: SPM 927
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03715582
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pills of masking drug - placebo
Trial: NCT00835718
Drug: Comparator: MK0594 5 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0594 5 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 15 mg MK0594 will be administered.
Trial: NCT00835718
Drug: Comparator: MK0594 1 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0594 1 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
Trial: NCT00835718
Drug: Comparator: MK0594 1 mg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0594 1 mg tablets taken orally once every 7 days for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
Trial: NCT00835718
Drug: Comparator: Placebo to MK0594
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to MK0594 tablets taken orally once daily for 12 weeks.
Trial: NCT03595449
Drug: Surgilube
RxNorm normalized name: Surgilube
FDA approved: no
EMA approved: no
PMDA approved: no
Description: surgilube (placebo) applied during Mohs surgery
Trial: NCT00433459
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: drug is used in first line treatment in combination (COPP or COPDAC)
Trial: NCT00433459
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
Trial: NCT00121199
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00121199
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02875678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose matching placebo
Trial: NCT01256476
Drug: pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg once daily (QD)
Trial: NCT01685203
Drug: ABT-450/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; ABT-450; Capsule; ritonavir
Trial: NCT01685203
Drug: ABT-267
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT03212599
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: alcohol addicted patients receive an oral Disulfiram application as recrudescence prevention after successful detoxication
Trial: NCT02669511
Drug: PQR309
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral PQR309, 80mg or 60mg daily or intermittent dosing
Trial: NCT02293148
Drug: GSK1278863 75 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
Trial: NCT02293148
Drug: GSK1278863 500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
Trial: NCT02293148
Drug: Placebo matching GSK1278863
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A round, biconvex, white film coated tablet as matching placebo for GSK1278863